Astex Pharmaceuticals announced data demonstrating for the first time that early treatment with AT13387, a second generation, fully synthetic HSP90 inhibitor, in combination with targeted therapy delays the emergence of resistance. In a preclinical model of mutant BRAF melanoma, animals were treated with vemurafenib alone or vemurafenib in combination with AT13387. After 2 to 4 months of continued treatment, tumor-bearing mice treated with vemurafenib alone showed the emergence of resistance and tumor regrowth while animals treated with the combination of vemurafenib and AT13387 did not show such regrowth. In addition, tumors that became resistant to vemurafenib alone were still sensitive to AT13387 treatment.
- Disease & Medical Conditions
- Astex Pharmaceuticals